Skip to main content
SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD logo

SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002737 ISIN · CNE100001WT7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,262 across all filing types
Latest filing 2025-10-27 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002737

About SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD

https://www.kuihuayaoye.com

Sunflower Pharmaceutical Group Co., Ltd. focuses on the research, development, manufacturing, and distribution of proprietary Chinese medicines, chemical drugs, and health supplements. The organization is particularly noted for its specialization in pediatric medicine, marketed under the "Little Sunflower" brand, which includes treatments for respiratory and digestive ailments. Its extensive product portfolio also covers gynecological health and general internal medicine. The group operates several integrated production bases and research institutes, facilitating a comprehensive approach to drug formulation and quality control. By leveraging a robust supply chain and a wide-reaching distribution network, the company provides a diverse range of over-the-counter and prescription solutions aimed at improving family health and wellness.

Recent filings

Filing Released Lang Actions
第五届监事会第六次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the resolution passed at the sixth meeting of the fifth Supervisory Board of the company. It specifically mentions the approval of the company's 2025 third quarter report by the Supervisory Board, confirming the report's compliance and accuracy. However, the document itself is not the quarterly report but an announcement of the Supervisory Board's meeting and its resolution regarding the report. The document length is short (657 characters), and it serves as a meeting resolution announcement rather than containing substantive financial data or the report itself. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for such announcements that do not fit other specific categories.
2025-10-27 Chinese
关于获得药物临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a company about receiving approval from the National Medical Products Administration for a clinical trial of a drug. It contains no financial data, no report or presentation, and is not related to shareholder meetings, earnings, or management changes. It is a regulatory announcement about a drug development milestone. The document length is short (857 characters) and it is an announcement of an event, not a report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-10-16 Chinese
对外投资管理办法（2025年10月）
Governance Information Classification · 95% confidence The document is titled '葵花药业集团股份有限公司 对外投资管理办法' which translates to 'Sunflower Pharmaceutical Group Co., Ltd. External Investment Management Measures'. It is a detailed internal policy document outlining the principles, decision-making authority, roles, execution controls, disposal, supervision, reporting, and disclosure related to the company's external investments. It references relevant laws and regulations but does not contain financial statements, earnings data, or audit information. It is not an announcement or a report of financial results, nor is it a regulatory filing or certification. It is a governance-related document detailing internal rules and procedures for managing external investments. Therefore, the most appropriate classification is Governance Information (CGR). The document length (4626 characters) and content confirm it is a full policy document, not a brief announcement or notice.
2025-10-10 Chinese
募集资金管理制度（2025年10月）
Capital/Financing Update Classification · 95% confidence The document is titled '募集资金管理制度' which translates to 'Fundraising Capital Management System' and details the rules and procedures for managing and using funds raised by the company through stock issuance or other equity securities. It references relevant laws and regulations, outlines the management of special accounts for raised funds, usage plans, approval processes, supervision, and reporting requirements. The content is a detailed internal policy or governance document related to capital raising and fund management rather than a financial report, announcement, or regulatory filing. It does not contain financial statements, earnings data, voting results, or audit opinions. It is not a report publication announcement or a certification. The document is a governance or management policy document concerning capital raising and fund usage. Therefore, the most appropriate classification is 'Capital/Financing Update (CAP)' as it relates to fundraising and capital management rules and procedures.
2025-10-10 Chinese
第五届董事会第十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 11th meeting of the 5th Board of Directors of a company, including approvals of related party transactions, amendments to the company charter, adjustments to management systems, and the proposal to convene an extraordinary shareholders meeting. It includes voting results and references to compliance with company law and internal governance. There is no financial data or report content, but rather a formal record of board decisions and governance matters. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors or senior management.
2025-10-10 Chinese
防止控股股东、实际控制人及其关联方资金占用管理办法（2025年10月）
Governance Information Classification · 95% confidence The document is titled as a management policy document regarding prevention of non-operating fund occupation by controlling shareholders and related parties. It contains detailed internal rules, principles, responsibilities, and supervisory measures related to corporate governance and financial management. There is no indication that this is an announcement, a financial report, or a regulatory filing. The content aligns with governance practices and internal control mechanisms. Therefore, the document fits best under Governance Information (CGR). The document length is 3383 characters, which is not very short, and it is a substantive policy document, not a mere announcement or certification.
2025-10-10 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.